Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma TrialRakesh Popat, Nicholas Counsell, Ruth de Tute et al.|British Journal of Haematology|2021Cited by 5
PMO-39 Factors influencing delays in biologic initiation in inflammatory bowel diseaseEleanor Liu, J K Limdi, Hassan Sattar et al.|Unknown|2021Cited by 4
OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DEFERRED ASCT (PADIMAC)Rickin Popat, Ruth de Tute, Dunnya De‐Silva et al.|St George's Online Research Archive (St George's University of London)|2017Cited by 0
Outcomes of newly diagnosed multiple myeloma with deferred ASCT after achieving ≥VGPR following PAD induction in the Phase 2 PADIMAC studyWei Yee Chan, Kwee Yong, Nicholas Counsell et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 0
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trialWei Yee Chan, Nicholas Counsell, Ruth de Tute et al.|British Journal of Haematology|2021Cited by 0